Characteristics of RSV-Specific Maternal Antibodies in Plasma of Hospitalized, Acute RSV Patients under Three Months of Age

Respiratory syncytial virus (RSV) is the leading cause for respiratory illness that requires hospitalization in infancy. High levels of maternal antibodies can protect against RSV infection. However, RSV-infected infants can suffer from severe disease symptoms even in the presence of high levels of RSV-specific antibodies. This study analyzes several serological characteristics to explore potential deficiencies or surpluses of antibodies that could relate to severe disease symptoms. We compare serum antibodies from hospitalized patients who suffered severe symptoms as well as uninfected infants. Disease severity markers were oxygen therapy, tachypnea, oxygen saturation, admission to the intensive care unit and duration of hospitalization. Antibodies against RSV G protein and a prefusion F epitope correlated with in vitro neutralization. Avidity of RSV-specific IgG antibodies was lower in RSV-infected infants compared to uninfected controls. Severe disease symptoms were unrelated to RSV-specific IgG antibody titers, avidity of RSV-IgG, virus neutralization capacity or titers against pre- and postfusion F or G protein ectodomains and the prefusion F antigenic site Ø. In conclusion, the detailed serological characterization did not indicate dysfunctional or epitope-skewed composition of serum antibodies in hospitalized RSV-infected infants suffering from severe disease symptoms. It remains unclear, whether specific antibody fractions could diminish disease symptoms.

[1]  G. Fuh,et al.  Erratum: Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation , 2016, Nature Medicine.

[2]  L. Bont,et al.  Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries , 2016, Infectious Diseases and Therapy.

[3]  F. V. van Kuppeveld,et al.  Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV , 2016, Journal of Virology.

[4]  R. Karron,et al.  Impact of Placental Malaria and Hypergammaglobulinemia on Transplacental Transfer of Respiratory Syncytial Virus Antibody in Papua New Guinea. , 2016, The Journal of infectious diseases.

[5]  P. González,et al.  Contribution of Fcγ receptors to human respiratory syncytial virus pathogenesis and the impairment of T‐cell activation by dendritic cells , 2016, Immunology.

[6]  G. Chuang,et al.  Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera , 2015, Science Translational Medicine.

[7]  H. Schuitemaker,et al.  A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism , 2015, Nature Communications.

[8]  P. Rottier,et al.  Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics , 2015, PloS one.

[9]  J. Wrammert,et al.  Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. , 2015, American journal of respiratory and critical care medicine.

[10]  R. Woodland,et al.  Murine Immune Responses to Virus-Like Particle-Associated Pre- and Postfusion Forms of the Respiratory Syncytial Virus F Protein , 2015, Journal of Virology.

[11]  J. Scott,et al.  Quantifying maternally derived respiratory syncytial virus specific neutralising antibodies in a birth cohort from coastal Kenya , 2015, Vaccine.

[12]  E. Walsh,et al.  Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. , 2014, The Journal of infectious diseases.

[13]  D. D. de Jong,et al.  Recognition of Streptococcus pneumoniae and Muramyl Dipeptide by NOD2 Results in Potent Induction of MMP-9, Which Can Be Controlled by Lipopolysaccharide Stimulation , 2014, Infection and Immunity.

[14]  P. Rottier,et al.  A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles , 2013, PloS one.

[15]  J. Stockman.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis , 2012 .

[16]  Y. van Remmerden,et al.  An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting , 2012, Virology Journal.

[17]  Deise A. O. Silva,et al.  Antibody response and avidity of respiratory syncytial virus‐specific total IgG, IgG1, and IgG3 in young children , 2011, Journal of medical virology.

[18]  P. Kwong,et al.  Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes , 2011, Journal of Virology.

[19]  P. Roholl,et al.  A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats , 2010, Virology Journal.

[20]  S. Madhi,et al.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis , 2010, The Lancet.

[21]  J. Zorc,et al.  Bronchiolitis: Recent Evidence on Diagnosis and Management , 2010, Pediatrics.

[22]  J. Stockman.  Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease , 2010 .

[23]  C. Uiterwaal,et al.  Respiratory Pathogens in Respiratory Tract Illnesses During the First Year of Life: A Birth Cohort Study , 2009, The Pediatric infectious disease journal.

[24]  Peter Aaby,et al.  Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze. , 2009, The Journal of allergy and clinical immunology.

[25]  K. O'Brien,et al.  Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. , 2008, The Journal of infectious diseases.

[26]  Katherine L. O'Brien,et al.  The Role of Neutralizing Antibodies in Protection of American Indian Infants Against Respiratory Syncytial Virus Disease , 2008, The Pediatric infectious disease journal.

[27]  S. J. Hoffman,et al.  A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease , 2002, The Journal of experimental medicine.

[28]  W. Gruber,et al.  Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. , 2002, The Journal of infectious diseases.

[29]  L. van Alphen,et al.  Antibody Avidity and Immunoglobulin G Isotype Distribution following Immunization with a Monovalent Meningococcal B Outer Membrane Vesicle Vaccine , 2002, Infection and Immunity.

[30]  J. Smith,et al.  Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus , 1996, Journal of virology.

[31]  J. Melero,et al.  Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. , 1992, The Journal of general virology.

[32]  E. Walsh,et al.  Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine , 1986, Journal of clinical microbiology.

[33]  A. Frank,et al.  Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. , 1981, The Journal of pediatrics.

[34]  R. Chanock,et al.  An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. , 1969, American journal of epidemiology.